Indeed, our study in breast cancer cells [7] and a report on high-risk myelodysplastic syndrome and acute myeloid leukaemia [24] confirm that targeting ATM abrogates canonical NF-κB signalling. This evidence concerns the gene NFKB1 and myelodysplastic syndrome.